UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CLINICAL RESEARCH

Accelsiors

Regulatory strategy and scientific affairs consultancy

Accelsiors logo

Accelsiors

Regulatory strategy and scientific affairs consultancy

Visit WebsiteContact Company

About Accelsiors

With more than two decades of experience accelerating clinical development for emerging biotech companies, Accelsiors operates as a full-service global Contract Research Organisation (CRO) built specifically around the needs of smaller, agile biopharma developers. The company positions itself as a strategic partner rather than a transactional vendor, offering smart, tailored solutions across the full development continuum.

Accelsiors delivers an extensive range of clinical trial services covering early-stage and late-stage development. Early-stage capabilities include project management, central and risk-based monitoring, regulatory monitoring and site management, data management, record management, safety management and pharmacovigilance, quality assurance, biostatistics, medical writing, and clinical pharmacology including modelling and simulation. Late-phase services extend to real-world evidence trials, with dedicated consultancy arms covering regulatory, medical and pharmacovigilance, legal and GDPR, and drug development consultancy. A functional service provider (FSP) model is also available for clients seeking embedded expertise rather than full outsourcing.

The company serves a broad span of therapeutic areas, including oncology, autoimmune disorders, infectious diseases, endocrinology, respiratory, hepatology and gastrointestinal, nervous system, nephrology, women's health, nephrology, biosimilars, generics, paediatrics, cell and gene therapy, vaccines, orphan disorders, and microbiome research. This breadth reflects the company's positioning as a single-partner solution for biotech pipelines spanning multiple indications.

Accelsiors has developed a suite of proprietary methodologies and platforms, among them Hexa-Helix, Quality Drive, StrongCORE Scientific, AcceleROUTE, WideSCOPE Intelligence, ProPATIENT Solutions, and AcceShield, each designed to support specific functions within the clinical development workflow.

Further information is available at accelsiors.com.

Areas of Expertise

BiostatisticsClinical Trial ManagementMedical WritingOncologyPharmacovigilanceRegulatory Affairs

Services & Capabilities

BiostatisticsClinical Trial ManagementMedical WritingOncologyPharmacovigilanceRegulatory Affairs
Similar Companies

More in Clinical Research

E

Excellerate Bioscience

Excellerate Bioscience was established in 2016 with a clear mandate: to bring together the best of academic and industrial drug discovery science within a single, agile contract research organisation. Headquartered in the United Kingdom, the company provides molecular and cellular pharmacology services to clients engaged in drug discovery, combining scientific creativity with collaborative working practices. The company's approach centres on improving the efficiency and translatability of in vitro pharmacological profiling. Its experienced team of drug discovery scientists is organised to deliver both rigour and flexibility, qualities that organisations working at early discovery stages often require from external partners. Excellerate Bioscience's service portfolio spans several key areas of preclinical research. Capabilities include molecular pharmacology, phenotypic assays, screening and assay development, and work across multiple drug modalities. The company also supports clients through distinct drug discovery phases, with therapeutic area coverage built into its project delivery model. This breadth allows it to serve partners from early target identification through to candidate selection. With its founding team drawn from both academic and pharmaceutical industry backgrounds, the organisation was built to address a recognised gap: providing high-quality, scientifically innovative pharmacology services with the responsiveness that larger service providers can struggle to match. The mission stated at formation remains central to how the company operates today. Further information is available at excelleratebio.com.

View profile
A

APCER Life Sciences

With a workforce comprising 100% healthcare professionals, including a 15% physician pool, APCER Life Sciences brings deep clinical and scientific expertise to every stage of the product lifecycle. The company is a specialist pharmacovigilance contract research organisation (CRO) serving pharmaceutical, biotech, and medical device partners across more than 100 markets worldwide. Over nearly two decades, APCER has built an integrated service model that spans the full spectrum of drug safety and regulatory requirements. Core capabilities include ICSR case processing, literature surveillance, aggregate reporting, signal management, and risk management programmes such as REMS. The company also provides QPPV and PSMF support, medical information through an integrated response centre, regulatory affairs, medical writing, and quality assurance, enabling sponsors to consolidate multiple functions under a single, accountable partner. Technology sits at the centre of the APCER model. The firm positions its solutions as fit-for-purpose technology-powered platforms, designed to meet the highest regulatory standards while offering clients scalable and flexible engagement models. This approach supports both small innovators and established organisations navigating complex global regulations. The company operates across North America, the United Kingdom, Europe, and Asia, and counts more than 90 customers within its client base. Its stated focus is on building strategic partnerships grounded in trust, transparency, and a customer-first mindset, with the overarching goal of helping safe and effective therapies reach patients worldwide. Further information is available at apcerls.com.

View profile
A

Alcyomics

Founded in 2007 as a spinout from Newcastle University, Alcyomics develops and delivers human in vitro assays that enable pharmaceutical, biotechnology, chemical, and cosmetic companies to detect adverse immune reactions early in the development process, reducing both risk and cost before clinical stages are reached. The company's scientific foundation was built by Professor Anne Dickinson, whose three decades of research into transplantation and graft-versus-host disease at Newcastle University produced skin-based assay methodologies that have demonstrated over 80% correlation with clinical outcomes. That research led directly to Alcyomics' flagship technology: the patented Skimune platform, a highly sensitive human in vitro skin assay that uses matched skin and blood from the same donor to predict immune responses to small and large molecule drugs, monoclonal antibodies, cellular therapies, and cosmetic compounds. Building on the core Skimune test, Alcyomics has expanded its model portfolio to include Skimune 3D, a high-throughput full-thickness skin equivalent developed in collaboration with REPROCELL, as well as an innervated skin model for neurotoxicity assessment and a bioprinted osteo-arthritic joint model aimed at transforming drug discovery for osteoarthritis. The company operates from state-of-the-art laboratories within The Biosphere in Newcastle upon Tyne, serving a global client base that includes top-tier pharmaceutical organisations. Further information is available at alcyomics.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy